Optimind Pharma Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OMND.CN research report →
Companyoptimindpharma.com
Optimind Pharma Corp. operates as a pharmaceutical company in Canada. The company offers psychedelic therapies for treatment of post-traumatic stress syndrome, anxiety, depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities.
- CEO
- David Goodman
- IPO
- 2022
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $515.74K
- P/E
- -11.00
- P/S
- 4.16
- P/B
- -6.43
- EV/EBITDA
- -10.97
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.51%
- Op Margin
- -35.99%
- Net Margin
- -37.80%
- ROE
- 68.83%
- ROIC
- -98.13%
Growth & Income
- Revenue
- $118.37K · -3.73%
- Net Income
- $-215,812 · 84.56%
- EPS
- $-0.00 · 86.43%
- Op Income
- $-215,812
- FCF YoY
- 54.30%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.14
- Avg Volume
- 5.09K
Get TickerSpark's AI analysis on OMND.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our OMND.CN Coverage
We haven't published any research on OMND.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OMND.CN Report →